R V Iaffaioli
Overview
Explore the profile of R V Iaffaioli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quagliariello V, DAiuto G, Iaffaioli R, Berretta M, Buccolo S, Iovine M, et al.
Eur Rev Med Pharmacol Sci
. 2021 Jun;
25(10):3898-3907.
PMID: 34109598
The World Cancer Research Fund and American Institute for Cancer Research (WCRF/AICR) advise cancer survivors to follow their lifestyle recommendations for cancer prevention. Recent research indicates that a proper diet...
2.
Quagliariello V, Bonelli A, Caronna A, Lombari M, Conforti G, Libutti M, et al.
Eur Rev Med Pharmacol Sci
. 2020 Sep;
24(17):9169-9171.
PMID: 32965010
NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be...
3.
Simonetti V, Quagliariello V, Franzini M, Iaffaioli R, Maurea N, Valdenassi L
Evid Based Complement Alternat Med
. 2019 Dec;
2019:2169103.
PMID: 31827546
Introduction: Skin reactions and cardiotoxicity are one of the most common side effects of doxorubicin in cancer patients. The main mechanisms based on the etiopathogenesis of these reactions are mediated...
4.
Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, et al.
Int J Cardiol
. 2019 Jun;
292:171-179.
PMID: 31160077
Background: The immunotherapy has revolutionized the world of oncology in the last decades with considerable advantages in terms of overall survival in cancer patients. The association of Pembrolizumab and Trastuzumab...
5.
Quagliariello V, Coppola C, Mita D, Piscopo G, Iaffaioli R, Botti G, et al.
Environ Toxicol Pharmacol
. 2019 Mar;
69:1-8.
PMID: 30903913
Endocrine disrupters are strictly associated to cancer and several cardiovascular risk factors. Bisphenol A (BPA) is an endocrine disrupter commonly used in the manufacturing of plastics based on polycarbonate, polyvinyl...
6.
De Divitiis C, von Arx C, Grimaldi A, Cicala D, Tatangelo F, Arcella A, et al.
J Transl Med
. 2016 May;
14(1):113.
PMID: 27142424
Neuroendocrine Neoplasms (NEN) are a group of heterogeneous malignancies derived from neuroendocrine cell compartment, with different roles in both endocrine and nervous system. Most NETs have gastroentero-pancreatic (GEP) origin, arising...
7.
Nasti G, Piccirillo M, Izzo F, Ottaiano A, Albino V, Delrio P, et al.
Br J Cancer
. 2013 Apr;
108(8):1566-70.
PMID: 23558891
Background: Preoperative treatment of resectable liver metastases from colorectal cancer (CRC) is a matter of debate. The aim of this study was to assess the feasibility and activity of bevacizumab...
8.
Rosso F, Quagliariello V, Tortora C, Di Lazzaro A, Barbarisi A, Iaffaioli R
J Mater Sci Mater Med
. 2013 Mar;
24(6):1473-81.
PMID: 23471500
This paper focused on the biodistribution of the cross-linked hyaluronic acid (HA-NPs) sub-micron particles in tumor-bearing mice. Solvent-non solvent method followed glutaraldehyde cross-linking utilized for the fabrication of HA-NPs. Size...
9.
Nasti G, Ottaiano A, Berretta M, Delrio P, Izzo F, Cassata A, et al.
Cancer Chemother Pharmacol
. 2010 Mar;
66(2):209-18.
PMID: 20333385
The standard treatment of CRC patients with hepatic metastases is systemic chemotherapy; however, 5-year survival is disappointingly poor despite recent advances. On the other hand, in patients who undergo immediate...
10.
Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, et al.
J Exp Clin Cancer Res
. 2007 Nov;
26(3):307-12.
PMID: 17987788
Current management of bone metastases involves a multimodal approach. Aminobisphosphonates (BPs) are a valid weapon in the treatment of skeletal localization of tumour disease. Patients with bone metastases from breast...